title: Chryseobacterium indologenes bacteremia in a bone marrow transplant recipient with chronic graft-versus-host disease.
abstract: We describe a case of Chryseobacterium indologenes bacteremia in a leukemia patient with chronic graft-versus-host disease (GVHD) 6 months after allogeneic bone marrow transplantation. Blood cultures from a vein and via Hickman catheter grew C. indologenes. The patient was successfully treated with piperacillin/tazobactam and the infection did not recur. Our case indicates that C. indologenes infection can occur in patients with GVHD after allogeneic BMT and might be treated with a single agent, piperacillin/tazobactam without the removal of intravascular catheter.
authors.affiliation: Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, National Yang-Ming University School of Medicine, Taipei, Taiwan. ljtmi@yahoo.com
authors.forename: Jen-Tsun
authors.initials: JT
authors.lastname: Lin
authors.forename: Wei-Shu
authors.initials: WS
authors.lastname: Wang
authors.forename: Chueh-Chuan
authors.initials: CC
authors.lastname: Yen
authors.forename: Jin-Hwang
authors.initials: JH
authors.lastname: Liu
authors.forename: Tzeon-Jye
authors.initials: TJ
authors.lastname: Chiou
authors.forename: Mu-Hua
authors.initials: MH
authors.lastname: Yang
authors.forename: Ta-Chon
authors.initials: TC
authors.lastname: Chao
authors.forename: Po-Min
authors.initials: PM
authors.lastname: Chen
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D016470:Bacteremia / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000379:methods; D002908:Chronic Disease; D045247:Chryseobacterium / Q000302:isolation & purification*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D045826:Flavobacteriaceae Infections / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000150:complications* / Q000175:diagnosis / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D008297:Male; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents